Stay updated with breaking news from Valuating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity, confirmed objective response rate
AstraZeneca PLC on Friday reported positive results from planned interim analysis of a phase three trial evaluating its Imfinzi drug in gastric and gastroesophageal junction cancers. The... | June 2, 2023
NORTH CHICAGO - AbbVie today announced the results of the Phase 2 SLEek study evaluating upadacitinib alone and in combination [ABBV-599 high dose ] in adults with moderately to severely active... | June 1, 2023
By Colin Kellaher Pfizer on Thursday reported positive results from a pair of Phase 3 studies evaluating the efficacy, safety and tolerability of the novel investigational antibiotic... | June 1, 2023
NEW YORK - TG Therapeutics, Inc. , today announced the details of an upcoming oral presentation, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI in patients with... | June 1, 2023